GLP-1 Discontinuation Linked to Increased Cardiovascular Risk

The Fragile Gains of GLP-1s: Why Stopping Treatment May Undo Heart Benefits

The growing popularity of GLP-1 receptor agonists – a class of drugs initially developed for diabetes, now widely used for weight management – comes with a crucial caveat: the cardiovascular benefits they offer appear to erode, and could even reverse, when treatment is stopped. New research published in BMJ Medicine highlights the importance of continuous use for maintaining heart health in individuals with type 2 diabetes, raising questions about adherence and long-term management strategies.

The findings underscore a growing concern among clinicians: while initiating GLP-1s generates considerable enthusiasm, less attention is paid to the potential consequences of discontinuation. Factors like cost, side effects, and even drug shortages can lead patients to pause or stop treatment, potentially negating the positive effects on cardiovascular risk. This isn’t simply about weight regain, which is well-documented; it’s about a broader metabolic shift that impacts blood pressure, cholesterol, and inflammation.

Cardiovascular Protection Tied to Consistent Use

Researchers analyzed data from the U.S. Department of Veterans Affairs, comparing cardiovascular outcomes – including stroke, myocardial infarction (heart attack), and death – between over 333,000 participants with type 2 diabetes. The study followed individuals from 2017 through 2023, comparing those prescribed GLP-1 receptor agonists to those prescribed sulfonylureas, another class of diabetes medication.

The analysis revealed a clear pattern: the longer a patient consistently used a GLP-1 receptor agonist, the greater the reduction in cardiovascular risk compared to those on sulfonylureas. Those who remained on GLP-1s for the entire three-year follow-up period experienced an 18% reduction in cardiovascular events. However, this protective effect diminished as treatment was interrupted.

Specifically, stopping GLP-1s for six months or more significantly raised the risk of adverse cardiovascular events. The risk increase grew with the duration of discontinuation: a 14% increase after one year, and a 22% increase after two years. Even shorter interruptions of six months were associated with a 4% increase in risk. These findings suggest that the metabolic benefits of GLP-1s aren’t simply additive over time, but rather require sustained activation to maintain their protective effects. Previous research has already established a link between stopping these medications and weight regain.

Metabolic “Whiplash” and the Challenge of Adherence

Ziyad Al-Aly, MD, a clinical epidemiologist at Washington University School of Medicine in Saint Louis, and lead author of the study, described the phenomenon as a “metabolic whiplash.” “Many quit after a few months because of cost, side effects or shortages,” he explained in a press release. “When they stop, it’s not just weight that comes back; they experience a resurgence in inflammation, blood pressure and cholesterol. Weight regain is visible; the metabolic reversal is not.” While restarting the medication offered some restoration of protection, it was incomplete, indicating that discontinuation leaves a lasting impact.

This raises a critical point about the nature of GLP-1 therapy. These drugs aren’t a “fix” to be applied briefly; they address chronic conditions requiring ongoing management. The study highlights the need for a shift in perspective, viewing adherence to GLP-1 treatment as a primary outcome in itself, rather than an afterthought.

Beyond Cardiovascular Risk: Implications for Pregnancy and Other Outcomes

The potential consequences of discontinuing GLP-1s extend beyond cardiovascular health. Recent research suggests that stopping these medications before or during pregnancy may increase the risk of adverse outcomes like gestational diabetes and preterm delivery. This underscores the importance of careful planning and communication with patients, particularly those who are considering pregnancy.

Understanding GLP-1s and Their Mechanism

GLP-1 receptor agonists mimic the effects of glucagon-like peptide-1, a natural hormone that regulates blood sugar, appetite, and insulin secretion. These medications work by stimulating insulin release when blood sugar is high, suppressing glucagon secretion (which raises blood sugar), and slowing down gastric emptying (the rate at which food leaves the stomach). These actions contribute to both weight loss and improved cardiovascular health. However, the precise mechanisms underlying the cardiovascular benefits are still being investigated.

Study Limitations and Future Directions

The researchers acknowledge several limitations to their study. The cohort consisted primarily of veterans, which may limit the generalizability of the findings to other populations. The study did not assess the reasons for GLP-1 discontinuation, nor did it analyze risks based on specific indications for the medication (e.g., diabetes vs. Obesity).

Further research is needed to understand the long-term effects of GLP-1 discontinuation across diverse populations and to identify strategies for improving adherence. This includes addressing cost barriers – out-of-pocket costs for GLP-1s are rising for many patients – and proactively managing side effects.

What This Means for Patients and Clinicians

The findings emphasize the need for open and honest conversations between patients and clinicians about the long-term nature of GLP-1 therapy. Healthcare systems should develop strategies to support patients in continuing their medication indefinitely, recognizing that these drugs treat chronic conditions. This includes proactive management of side effects, addressing cost concerns, and identifying patients at risk of stopping treatment. The World Health Organization’s conditional recommendation for using GLP-1s to treat obesity worldwide further underscores their potential, but also highlights the need for careful consideration of long-term management.

maximizing the benefits of GLP-1s requires a commitment to sustained treatment and a proactive approach to addressing the challenges of adherence.